36 related articles for article (PubMed ID: 38488039)
21. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
[TBL] [Abstract][Full Text] [Related]
22. Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy.
Tatenuma T; Miyamoto H
Drug Des Devel Ther; 2023; 17():2325-2333. PubMed ID: 37559910
[TBL] [Abstract][Full Text] [Related]
23. Advances with androgen deprivation therapy for prostate cancer.
Yu EM; Aragon-Ching JB
Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
[TBL] [Abstract][Full Text] [Related]
24. Adherence to Hormonal Therapies in Prostate Cancer.
Hafron J; Sangha P; Kung T; Pruett J
Urol Pract; 2023 Nov; 10(6):540-546. PubMed ID: 37647139
[TBL] [Abstract][Full Text] [Related]
25. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
26. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
27. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
28. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
29. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.
Nair B; Wilt T; MacDonald R; Rutks I
Cochrane Database Syst Rev; 2002; (1):CD003506. PubMed ID: 11869665
[TBL] [Abstract][Full Text] [Related]
30. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
31. Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis.
Kunath F; Borgmann H; Blümle A; Keck B; Wullich B; Schmucker C; Sikic D; Roelle C; Schmidt S; Wahba A; Meerpohl JJ
BMJ Open; 2015 Nov; 5(11):e008217. PubMed ID: 26567252
[TBL] [Abstract][Full Text] [Related]
32. Evaluating relugolix for the treatment of prostate cancer in real-world settings of care: the OPTYX study protocol.
Spratt DE; Dorff T; McKay RR; Lowentritt BH; Fallick M; Gatoulis SC; Flanders SC; Ross AE
Future Oncol; 2024 Apr; 20(12):727-738. PubMed ID: 38488039
[TBL] [Abstract][Full Text] [Related]
33. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
34. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
35. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]